Behind Research’s Wild M&A Week / RBDR

Do you regularly watch RBDR, whether once or up to four times a week? Do you find it informative and entertaining? Help maintain and continue our video based on what you can afford (e.g., $5 or $10 for an individual, perhaps $25 to $50 from a business per month). Visit


November 17, 2021

Today on RBDR: There were five major M&A research deals last week, and it is at least partially explained by legacy companies in need of transformational capabilities and their zeroing in on their prey: smaller research suppliers that cannot scale up and thrive longterm.

No need to spend time searching for today’s RBDR video. Subscribe to receive a FREE, personal email as soon as the latest RBDR is uploaded. Click here:

(PMVR 10.20.2014) Matt Campion reveals meanings of KOL has been evolving.

To subscribe to PRVR and receive an email with multiple links to the latest video report, please click:

Pharma Research VIDEO Report, a co-partnered production with the Pharmaceutical Marketing Research Group, is sponsored this week by the Toluna Healthcare Practice, offering highly engaged physicians, health professionals and ailment sufferers for global research using cutting-edge methodologies, sophisticated, yet easy-to-use analytic tools and specialized products including Pharmacy Intercept, dedicated communities, patient record studies and more.

Find everything you could want to know about the Toluna Healthcare Practice at its homepage:

1) CVS Health has 41 partnerships in place with health system partners to try to stem readmittance to hospitals by better understanding Rx complications.


2) The Sunshine Act’s Open Payment website revises its 2013 reported payment by pharmaceutical companies to MDs, adding $1.1 billion to the $3.5 billion initially reported.


3) Stanford University’s new Center for Medical Mobile Technology will capture measurable, meaningful wearable device data.


4) Schlesinger Associates’ Matt Campion speaks to PRVR about KOLs and their variable importance among pharmaceutical market research stakeholders.